

Executive Steering Committee Elections 2026

Nominee Name: Roy Shay

Current Position/Title: VP Biodefense

BioMaP-Consortium Member Organization: Rafa Laboratories Ltd.

ESC Seat Applying for: Voice of Membership (i.e., Member-At-Large)

Please describe how your background, training, and experience would support your ability to serve in a governance role on the Executive Steering Committee.

My background combines biotechnology innovation, pharmaceutical development, entrepreneurship, and business strategy, providing a multidisciplinary perspective well suited to governance on the Executive Steering Committee. As Vice President of Biodefense at Rafa Laboratories, I lead programs spanning product development, regulatory strategy, government engagement, and commercialization of FDA-approved medical countermeasures. This role requires balancing scientific, operational, regulatory, and strategic considerations while working with government agencies, healthcare stakeholders, and international partners to advance solutions that strengthen preparedness and public health resilience.

Earlier in my career, I held business development roles at MSD (Merck & Co.) and Neopharm Group, where I gained experience in healthcare innovation, strategic partnerships, and commercialization. I also founded and led an agricultural technology company, providing firsthand experience in entrepreneurship, technology development, and organizational leadership. Combined with my scientific training at the Weizmann Institute of Science and my ongoing focus on biodefense and emergency preparedness, these experiences enable me to contribute thoughtful strategic oversight, foster cross-sector collaboration, and support sound governance decisions that advance the Consortium's mission.

Please describe the relevant experience, expertise, and perspective you would bring to the ESC seat you selected.

Throughout my career, I have worked at the intersection of biotechnology, pharmaceuticals, government engagement, and commercialization, collaborating with a broad range of stakeholders across industry, healthcare, academia, and government. In my current role as Vice President of Biodefense at Rafa Laboratories, I regularly engage with government agencies, international partners, healthcare organizations, and commercial collaborators to align diverse priorities and advance medical countermeasure programs. This experience has reinforced the importance of open communication, transparency, and

consensus-building qualities that are essential for representing the interests of a diverse consortium membership.

As the Voice of Membership (Member-at-Large), I would bring a practical, collaborative perspective focused on ensuring that members' needs and ideas are heard and reflected in the Consortium's activities. Having worked in both large pharmaceutical organizations and entrepreneurial environments, I understand the differing perspectives and challenges faced by organizations of varying sizes and missions. I would strive to strengthen communication between members, ATI, and U.S. Government stakeholders, encourage active engagement across the Consortium, and help ensure that BioMaP continues to provide meaningful value while advancing its mission of accelerating innovation in biodefense and public health preparedness.